What is the real cost of delayed Pharmacovigilance (PV) launch readiness?
Most pharmaceutical launch delays and failures are not driven by clinical setbacks but are caused by hidden gaps in commercial compliance readiness.
There are four predictable, high-stakes moments in the clinical-to-commercial journey where unprepared companies experience a crisis, while prepared companies experience a quiet, manageable non-event.
PV is frequently treated as a downstream requirement rather than the very first gate to commercialization. By the time the alarms sound, the damage to your timeline, budget, and funding story has already been done.
Download the full article to explore the four critical points where unprepared PV gets expensive.
EVERSANA is here to help biopharma companies eliminate the “hidden tax” of fragmented vendors by integrating PV, Quality, Regulatory, and Medical Information into a single, predictable, and fully orchestrated compliance foundation.
Want to explore these strategies with our experts and ask your most pressing questions? Dive deeper into this matter during our live webinar, Is Your PV Launch Ready?, on June 22nd.
Author
Dr. Vivek Ahuja serves as EVERSANA’s Executive Vice President of Compliance Services with over 22 years of experience across multiple functional offerings including Pharmacovigilance, Clinical Research, Technology, and Public Health. A physician by education…